FDA Issues Human Factors Guidance for Device Makers
Published Date: 5/29/2026
Notice
Summary
The FDA just released new guidance to help medical device makers include the right human factors info in their marketing submissions. This makes the review process faster and clearer for everyone involved. If you make or review medical devices, get ready to follow these updated steps starting now—saving time and possibly money!
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
New Human Factors Submission Framework
On May 29, 2026, FDA issued final guidance that gives a risk-based framework describing the human factors information medical device manufacturers should include in marketing submissions to the Center for Devices and Radiological Health (CDRH). The guidance is intended to help make the FDA review process more efficient by clarifying what human factors content belongs in a submission.
60-Day Operationalization and Grace Period
FDA says the Agency and industry may need a minimum of 60 days to operationalize the policies in the guidance. For regulatory submissions currently pending after publication and for submissions received before August 1, 2026, FDA generally does not expect manufacturers will be ready to include the newly recommended information, though FDA will review any such information if it is submitted.
No New Paperwork Burden Declared
The guidance states it contains no new collection of information under the Paperwork Reduction Act. It refers to previously approved FDA collections with OMB control numbers such as 0910-0120, 0910-0231, 0910-0332, and others.
Guidance Is Nonbinding; Alternatives Allowed
FDA states the guidance represents its current thinking and is not binding on FDA or the public. Manufacturers may use an alternative approach if that approach satisfies the applicable statutes and regulations.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-10732, Information Collection Requirement; Defense Federal Acquisition Regulation Supplement (DFARS), Contract Financing
The Department of Defense is asking to keep collecting info from businesses about contract payments for three more years. This affects about 1,000 companies who respond around 14,000 times a year, spending about 1.2 hours each time. They want your thoughts by July 28, 2026, to make sure the process stays useful and not too time-consuming.
Next: 2026-10735, Obayashi-Jay Dee Joint Venture; Application for Permanent Variance and Interim Order; Grant of Interim Order; Request for Comments
The Obayashi-Jay Dee Joint Venture asked OSHA for special permission to change some safety rules while working in compressed-air environments on a tunnel project in New Hampshire. OSHA gave them a temporary green light starting May 29, 2026, while they decide if this change can be permanent. Workers and the public can share their thoughts by June 29, 2026, so everyone stays safe and the project keeps moving.